Skip to main content

REVIEW article

Oncol.Rev.
Sec. Oncology Reviews: Reviews
Volume 18 - 2024 | doi: 10.3389/or.2024.1451247

Tracheal tumors: Clinical Practice Guidelines for palliative treatment and follow-up

Provisionally accepted
Aleksandra Piórek Aleksandra Piórek *Adam Płużański Adam Płużański Magdalena Knetki-Wróblewska Magdalena Knetki-Wróblewska Kinga Winiarczyk Kinga Winiarczyk Sylwia Tabor Sylwia Tabor Dariusz M. Kowalski Dariusz M. Kowalski Maciej Krzakowski Maciej Krzakowski
  • Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

The final, formatted version of the article will be published soon.

    A substantial portion of patients with advanced cancer cannot be cured, regardless of the therapeutic methods employed. Hence, rational palliative causal treatment becomes crucial.Representative studies specifically addressing the exclusive palliative treatment of patients diagnosed with tracheal cancers have not been identified. In most studies, patients treated palliatively constituted a subset of the overall evaluated group. A thorough literature review was conducted, focusing on three types of palliative treatment: palliative radiotherapy, palliative surgical procedures, and systemic treatment for advanced disease. This review uniquely fills a significant gap in the existing literature by providing the first comprehensive and updated clinical practice guidelines specifically focused on the palliative treatment of tracheal tumors. The proposed guidelines emphasize the unique clinical challenges and treatment strategies pertinent to palliative care in tracheal tumors, which are not adequately covered in existing guidelines for other thoracic malignancies.

    Keywords: Adenoid cystic carcinoma, follow-up, guideline, palliative treatment, squamouscell carcinoma of the trachea, Tracheal cancer

    Received: 18 Jun 2024; Accepted: 23 Aug 2024.

    Copyright: © 2024 Piórek, Płużański, Knetki-Wróblewska, Winiarczyk, Tabor, Kowalski and Krzakowski. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Aleksandra Piórek, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.